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Abstract
Interaction between the receptor for advanced glycation end products (RAGE) and its lig-
ands has been implicated in the pathogenesis of various inflammatory disorders. In this study, we
establish an in vitro binding assay in which recombinant human high-mobility group box 1 (rhH-
MGB1) or recombinant human S100A12 (rhS100A12) immobilized on the microplate binds to
recombinant soluble RAGE (rsRAGE). The rsRAGE binding to both rhHMGB1 and rhS100A12
was saturable and dependent on the immobilized ligands. The binding of rsRAGE to rhS100A12
depended on Ca2 and Zn2, whereas that to rhHMGB1 was not. Scatchard plot analysis showed
that rsRAGE had higher affinity for rhHMGB1 than for rhS100A12. rsRAGE was demonstrated
to bind to heparin, and rhS100A12, in the presence of Ca2, was also found to bind to heparin.
We examined the effects of heparin preparations with different molecular sizesunfractionated na-
tive heparin (UFH), low molecular weight heparin (LMWH) 5000Da, and LMWH 3000Da on the
binding of rsRAGE to rhHMGB1 and rhS100A12. All 3 preparations concentration-dependently
inhibited the binding of rsRAGE to rhHMGB1 to a greater extent than did rhS100A12. These
results suggested that heparin’s anti-inflammatory effects can be partly explained by its blocking
of the interaction between HMGB1 or S100A12 and RAGE. On the other hand, heparin would be
a promising effective remedy against RAGE-related inflammatory disorders.
KEYWORDS: RAGE, HMGB1, S100A12, heparin, inflammation
Establishment of in Vitro Binding Assay of High Mobility Group 
Box-1 and S100A12 to Receptor for Advanced Glycation 
Endproducts: Heparin’s Effect on Binding
Rui Liua,b,  Shuji Moric,  Hidenori Wakeb,  Jiyong Zhangb,   
Keyue Liub,  Yasuhisa Izushib,  Hideo K. Takahashib,  Bo Penga,  and Masahiro Nishiborib＊
aShanghai University of Traditional Chinese Medicine,  Shanghai 201-203,  China,  bDepartment of Pharmacology,   
Okayama University Graduate School of Medicine,  Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan,  and  
cShujitsu University,  School of Pharmacy,  Okayama 703-8516,  Japan
Interaction between the receptor for advanced glycation end products (RAGE) and its ligands has been 
implicated in the pathogenesis of various inﬂammatory disorders.  In this study,  we establish an in 
vitro binding assay in which recombinant human high-mobility group box 1 (rhHMGB1) or recombi-
nant human S100A12 (rhS100A12) immobilized on the microplate binds to recombinant soluble RAGE 
(rsRAGE).  The rsRAGE binding to both rhHMGB1 and rhS100A12 was saturable and dependent on the 
immobilized ligands.  The binding of rsRAGE to rhS100A12 depended on Ca2＋ and Zn2＋,  whereas that 
to rhHMGB1 was not.  Scatchard plot analysis showed that rsRAGE had higher aﬃnity for rhHMGB1 
than for rhS100A12.  rsRAGE was demonstrated to bind to heparin,  and rhS100A12,  in the presence of 
Ca2＋,  was also found to bind to heparin.  We examined the eﬀects of heparin preparations with diﬀer-
ent molecular sizes－unfractionated native heparin (UFH),  low molecular weight heparin (LMWH) 
5000 Da,  and LMWH 3000 Da－ on the binding of rsRAGE to rhHMGB1 and rhS100A12.  All 3 prepa-
rations concentration-dependently inhibited the binding of rsRAGE to rhHMGB1 to a greater extent 
than did rhS100A12.  These results suggested that heparinʼs anti-inﬂammatory eﬀects can be partly 
explained by its blocking of the interaction between HMGB1 or S100A12 and RAGE.  On the other 
hand,  heparin would be a promising eﬀective remedy against RAGE-related inﬂammatory disorders.
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he receptor for advanced glycation end products 
(RAGE) is a member of the immunoglobulin 
superfamily of cell-surface molecules,  which has been 
suggested to be involved in sustaining and amplifying 
inﬂammatory responses [1,  2].  RAGE can recognize 
a wide range of endogenous ligands,  such as advanced 
glycation end products (AGEs),  amyloid-β peptide (A
β),  high mobility group box 1 (HMGB1),  and the 
S100/calgranulin family [3].  RAGEʼs structure 
includes an extracellular immunoglobulin-like region 
essential for its binding to ligands,  a single trans-
membrane domain,  and a short cytoplasmic tail 
responsible for RAGE-mediated signal transduction 
[4].  There are soluble forms of RAGE－endogenous 
secretory RAGE (esRAGE) and soluble RAGE 
(sRAGE)－that lack a transmembrane domain and act 
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as decoy receptors [5].  The binding of ligands to 
RAGE triggers intracellular signaling such as nuclear 
factor kappa B (NF-κB) and mitogen-activated protein 
kinase (MAPK) activation in vascular endothelial cells 
and macrophages,  leading to the development of 
inﬂammation-based diseases,  such as diabetic compli-
cations,  sepsis,  Alzheimerʼs and rheumatic arthritis 
[6-9].  As a result,  interfering with the binding of 
ligands to RAGE has been thought to be a means with 
which to block the inﬂammatory responses sustained 
by RAGE-dependent pathways.
　 Among the RAGE ligands,  AGEs are the groups 
of nonenzymatically glycosylated proteins that accu-
mulate in vascular tissue in a wide variety of disor-
ders,  especially in diabetes [10].  HMGB1 is a ubiq-
uitous and abundant nuclear protein,  which can be 
passively released from necrotic cells and actively 
secreted by macrophages.  After HMGB1 is released 
into the extracellular environment,  it functions as a 
pro-inﬂammatory mediator [11,  12].  S100/calgranu-
lin is a multigenic family of EF-hand Ca2＋-binding 
proteins [13].  S100A12 is one member of the S100 
protein family,  which is found mainly in neutrophil 
granulocytes and monocytes [14].  S100A12 has a role 
in cell homeostasis as an intracellular molecule,  but 
contributes to the pathogenesis of inﬂammatory lesions 
via interaction with RAGE after release to the extra-
cellular compartment [15].
　 Heparin is a highly sulfated glycosaminoglycan,  
which has been traditionally used clinically as an 
anticoagulant [16].  It is biosynthesized and stored in 
the granules of mast cells [17].  More recent studies 
have highlighted the role of heparin as an anti-inﬂam-
matory substance that has been used in the treatment 
of some inﬂammatory settings [18-20].  However,  the 
molecular mechanisms underlying the anti-inﬂamma-
tion activities of heparin remain to be determined.  
Antagonism of AGEʼs eﬀect by LMWH in vivo has been 
reported [21].  A similar eﬀect of heparin on AGE-
RAGE signaling also has been demonstrated by the 
inhibition of RAGE-dependent NF-κB activation in 
glioma cells and expression of vascular cell adhesion 
molecule-1 (VCAM-1) and vascular endothelial growth 
factor (VEGF) in endothelial cells.  HMGB1 has also 
been described as a heparin-binding protein [22-24].  
Therefore,  heparin may be an important regulator of 
RAGE-mediated responses through multiple ligands.
　 To investigate the complex binding properties of 
RAGE to many ligands,  we attempted to establish in 
vitro binding of sRAGE to HMGB1 and S100A12 
using a microplate.  Both in vitro binding assays were 
saturated in terms of sRAGE and ligands.  We clearly 
showed Ca2＋,  Zn2＋-dependent binding of S100A12 to 
sRAGE.  We also observed the binding inhibition 
activity of each of the 3 heparin preparations,  sug-
gesting a mechanism for heparinʼs anti-inﬂammatory 
activity.  This may provide insights into potential uses 
of heparin in some RAGE-related pathologies.
Materials and Methods
　 Materials. Recombinant plasmid pASK-
IBA32-sRAGE was transformed into E.coli BL 21 
(DE3) (Merck,  San Diego,  LA),  and recombinant 
sRAGE (rsRAGE) proteins with a 6-histidine tag 
were expressed.  rsRAGE proteins were partially 
puriﬁed by using a Ni-NTA column and further puri-
ﬁed by heparin-sepharose aﬃnity chromatography.  
Recombinant plasmids pGEX-6P-1-HMGB1 and 
pGEX-6P-1-S100A12 were transformed into E.coli 
BL 21 (DE3).  Recombinant human HMGB1 (rhH-
MGB1) and recombinant human S100A12 
(rhS100A12) proteins were expressed as GST-
HMGB1 or GST-S100A12 fusion proteins,  respec-
tively.  GST tag was cleaved by protease in Glutath-
ione SepharoseTM 4B columns.  Unfractionated heparin 
(UFH) (mol wt: 12000～15000 Da),  low molecular 
weight heparin (LMWH) (mol wt: 5000 Da or 
3000 Da),  and bovine serum albumin (BSA) were pur-
chased from Sigma-Aldrich (St.  Louis,  MO, USA).  
2,  2ʼ-Azino-bis (3-ethylbenzthiazoline-6-sulphonic 
acid) (ABTS) was a product of Tokyo Kasei.  Kogyo.  
(Tokyo,  Japan).  Ni-NTA HRP Conjugate was from 
QIAGEN (Hilden,  Germany).  A 96-well ELISA plate 
(SUMILON®,  MS-8696F) was purchased from 
Sumitomo Bakelite (Tokyo,  Japan).
　 Binding assay of rsRAGE to rhHMGB1 or 
rhS100A12. A ﬂat-bottom 96-well plate was 
coated overnight with various concentrations of rhH-
MGB1 or rhS100A12 at 4°C (50µl/well).  Control 
wells received only PBS (50µl/well).  The plates were 
washed with PBS (200µl/well) 3 times and blocked 
with 10ｵ（w/v）BSA in PBS (100µl/well) for 2h 
at room temperature.  After unbound rhHMGB1 or 
rhS100A12 was washed oﬀ,  diﬀerent concentrations 
of rsRAGE diluted with 10ｵ BSA in PBS were 
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added into wells in triplicate (50µl/well),  and incuba-
tion continued overnight at 4°C.  Unbound rsRAGE 
was removed by washing 3 times with PBS at room 
temperature.  Ni-NTA HRP Conjugate 1/500 diluted 
by 0.2ｵ BSA in PBS (100µl/well) was added to the 
wells and incubated for 2h at 4°C.  After washing with 
PBS,  substrate solution,  0.1ｵ ABTS dissolved in 
20mM phosphate-citrate buﬀer (pH5.0) was added to 
each well (50µl/well) and incubated for 30min at room 
temperature.  Finally,  a stop solution of 1ｵ SDS was 
added (100µl/well).  The absorbance was measured at 
415nm in a microplate reader (Model 680) from Bio-
Rad Laboratories (Hercules,  CA, USA).
　 To determine the eﬀects of divalent cations on the 
binding,  experiments for rsRAGE binding to rhH-
MGB1 were performed with PBS buﬀer containing no 
divalent cations; 1mM CaCl2; 1mM CaCl2 and 10µM 
ZnCl2 throughout,  and the experiments for rsRAGE 
binding to rhS100A12 were performed with PBS 
buﬀer containing no divalent cations; 1mM CaCl2;  
1mM CaCl2 and 0.5mM MgCl2; 1mM CaCl2 and 
10µM ZnCl2; 1mM CaCl2 and 0.5mM MgCl2 and 
10µM ZnCl2 throughout.  rsRAGE and rhHMGB1 
were incubated for 24h,  48h,  and 72h at 4°C,  
respectively,  to determine the eﬀect of incubation 
time on the binding of rsRAGE to rhHMGB1.
　 rsRAGE was puriﬁed by heparin-sepharose 
aﬃnity chromatography. rsRAGE,  partially 
puriﬁed by using a Ni-NTA column,  was further puri-
ﬁed by heparin-sepharose aﬃnity chromatography.  
Heparin-sepharose CL-6B (GE Healthcare,  Milwau-
kee,  WI,  USA) was poured into the column and equi-
librated with 20mM phosphate buﬀer (pH7.4) contain-
ing 150mM NaCl.  rsRAGE was mixed with heparin-
sepharose for 3h at 4°C.  The supernatant was 
removed after centrifugation for 15min at 1,500rpm.  
rsRAGE was eluted with buﬀer containing 600mM 
NaCl after washing with buﬀer containing 150mM 
NaCl.  Puriﬁed rsRAGE was analyzed by SDS-
PAGE.
　 Binding of rhS100A12 to heparin-
sepharose. 100µl of 50ｵ heparin-sepharose 
slurry was washed with 200µl PBS by centrifugation 
at 1,500rpm for 5min twice.  PBS containing 1mM 
EDTA,  no divalent cations,  or 1mM Ca2＋ was used 
throughout the experiment.  To the washed gel was 
added 200µl of rhS100A12.  Samples were mixed in 
rotation at 4°C for 3h.  The supernatant and the sep-
harose gel were incubated with SDS-PAGE sample 
buﬀer at 99°C for 5min in a shaker.  Then,  15µl of 
each sample was electrophoresed by SDS-PAGE.
　 The eﬀects of diﬀerent preparations of hepa-
rin with diverse molecular weights on the bind-
ing of rsRAGE to rhHMGB1 or rhS100A12.
rhHMGB1 or rhS100A12 was coated on the plate as 
described above.  Then,  25µg/ml rsRAGE was incu-
bated with various concentration of heparin prepara-
tions diluted by 10ｵ BSA in PBS for 30min at 4°C,  
and the mixture was added to the plate (50µl/well).  
The following procedures were the same as those 
described above in the binding assay.
Results
　 rsRAGE binding to rhHMGB1. Diﬀerent 
concentrations of rhHMGB1 were immobilized on 
96-well plates,  and then various concentrations of 
rsRAGE were added to the plate.  Bound sRAGE was 
determined by the addition of Ni-NTA HRP followed 
by the peroxidase reaction.  The total binding was 
dependent on both rhHMGB1 and rsRAGE (Fig.  1A).  
The binding was saturable with respect to the 
rsRAGE concentration (Fig.  1B).  The values of 
nonspeciﬁc binding in the absence of rhHMGB1 were 
very small compared with the speciﬁc binding.  The 
inset shows a Scatchard plot of the speciﬁc binding 
obtained with rhHMGB1 at 6µg/ml for coating.  The 
Kd value of sRAGE for rhHMGB1 determined from 
the Scatchard analysis was 0.71µM.  rsRAGE bound 
to rhHMGB1 also in a time-dependent manner (Fig.  
2).  The presence of Ca2＋ (1mM) on the combination 
did not inﬂuence the binding of rsRAGE to rhHMGB1 
(Fig.  3).
　 rsRAGE binding to rhS100A12. Since 
S100A12 has been demonstrated to be a Ca2＋- and 
Zn2＋-binding EF-hand protein [28],  we examined the 
eﬀects of divalent cations on rsRAGE binding to 
rhS100A12.  Ca2＋ (1mM) alone signiﬁcantly increased 
the binding of rsRAGE to rhS100A12,  by 3-fold.  
Zn2＋ (10µM) further enhanced binding,  while Mg2＋ 
(0.5mM) had no eﬀect on it (Fig.  4).  These results 
implied that Ca2＋- and Zn2＋-bound conformation of 
S100A12 is required for the optimal binding to 
rsRAGE.  Fig.  5A shows the total and speciﬁc binding 
of rsRAGE to immobilized rhS100A12 (2µg/ml,  
10µg/ml,  and 50µg/ml for the coating plate) in the 
205Binding Assay of HMGB1 and S100A12 to RAGEAugust 2009
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presence of Ca2＋ and Zn2＋.  The Kd value of rsRAGE 
for rhS100A12 binding was determined to be 1.39µM 
by Scatchard analysis,  as shown in the inset (Fig.  
5B).
　 rsRAGE was puriﬁed by heparin-sepharose 
aﬃnity chromatography. The fractions obtained 
from heparin-sepharose aﬃnity chromatography were 
run on SDS-PAGE gels under denaturing conditions.  
Coomassie brilliant blue staining showed the presence 
of rsRAGE with a molecular size of 45000 Da (Fig.  
6),  which strongly suggested that rsRAGE can be 
regarded as a heparin-binding protein.
　 rhS100A12 binding to heparin-sepharose.
After rhS100A12 was incubated with heparin-sephar-
ose,  the supernatant and the sepharose gel were ana-
lyzed by SDS-PAGE under denaturing conditions and 
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Fig. 1　 Concentration-dependent binding of rsRAGE to rhHMGB1.  (A) Diﬀerent concentrations of rhHMGB1 were immobilized onto the 
wells of a 96-well plate.  After blocking the plate with 10% BSA/PBS,  the indicated concentrations of rsRAGE were added to the wells.  
The bound rsRAGE was quantiﬁed as described in Methods.  The results were the means ± SEM of 3 independent experiments.  (B) 
Speciﬁc binding of rsRAGE to rhHMGB1 was calculated by subtracting nonspeciﬁc binding in the absence of rhHMGB1 from the total bind-
ing with 6μg/ml of rhHMGB1.  The inset shows the Scatchard plot of the saturation curve.  The Kd value of rsRAGE for rhHMGB1 binding 


















Fig. 2　 Time-dependent binding of rsRAGE to rhHMGB1.  First,  
3μg/ml of rhHMGB1 was immobilized onto each well of a 96-well 
plate.  After the plate was blocked with 10% BSA/PBS,  25μg/ml 
of rsRAGE was added to each well and the incubation continued for 
24h,  48h,  and 72h at 4°C.  The results were the means ± SEM of 
3 independent experiments.  ＊P＜0.05,  ＊＊P＜0.01 compared with 













: no divalent cations : Ca2＋ : Ca2＋, Zn2＋
Fig. 3　 The eﬀects of Ca2＋ and Zn2＋ on rsRAGE binding to rhH-
MGB1.  The plate was coated with 6μg/ml rhHMGB1,  and 
12.5μg/ml rsRAGE was added to each well.  1mM Ca2＋ and 10μM 
Zn2＋ were added to the well indicated at the start of plate coating 
and were present throughout the period immediately before the ﬁnal 
reaction.  The results were the means ± SEM of 3 independent 
experiments.
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Coomassie brilliant blue staining.  rhS100A12 bound 
to heparin-sepharose also in a Ca2＋-dependent manner.  
A band was obtained with a molecular size of 
11000 Da in the presence of Ca2＋,  while there was no 
clear band in the presence of EDTA or in the absence 
of Ca2＋ (Fig.  7).
　 Heparin inhibits the binding of rsRAGE to 
rhHMGB1. The eﬀects of each of the 3 prepara-
tions of heparin with diﬀerent average molecular 
weights on rsRAGE binding to rhHMGB1 were exam-
ined.  The concentrations of rhHMGB1 and rsRAGE 
were ﬁxed at 3µg/ml and 25µg/ml,  respectively.  All 
3 preparations concentration-dependently inhibited the 
binding of rsRAGE to rhHMGB1 from 0.5 to 2µg/ml 
(Fig.  8).  The rank order of inhib itory potency was 
UFH,  LMWH 5000 Da,  and LMWH 3000 Da.
　 Heparin inhibits the binding of rsRAGE to 
rhS100A12. The eﬀects of the 3 preparations of 
heparin with diﬀerent average molecular weights on 
the binding of rsRAGE to rhS100A12 were evaluated 
in the presence of 1mM Ca2＋ and 10µM Zn2＋.  The 
concentrations of S100A12 and rsRAGE were ﬁxed at 
50µg/ml and 25µg/ml,  respectively.  Similar to the 
eﬀects on the binding of rhHMGB1 to rsRAGE,  all 3 
preparations concentration-dependently inhibited the 
binding of rsRAGE to rhS100A12 (Fig.  9).  However,  
the inhibitory potency against S100A12 binding was 
much lower than that against HMGB1 binding,  and 
that was common to all 3 preparations.  Even at 
100µg/ml of heparin,  the inhibition was about 50ｵ,  
irrespective of the preparation.
Discussion
　 RAGE is a transmembrane protein and has been 
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Fig. 5　 Concentration-dependent binding of rsRAGE to rhS100A12.  (A) Diﬀerent concentrations of rhS100A12 were immobilized onto the 
wells of a 96-well plate in the presence of 1mM Ca2＋,  10μM Zn2＋,  and 0.5mM Mg2＋.  After the plate was blocked with 10% BSA/PBS,  
the indicated concentrations of rsRAGE were added to the wells.  Ca2＋,  Zn2＋,  and Mg2＋ were present throughout the period immediately 
before the ﬁnal reaction.  The results were the means ± SEM of 3 independent experiments.  (B) Speciﬁc binding of rsRAGE to rhS100A12 
was calculated by subtracting nonspeciﬁc binding in the absence of rhHMGB1 from the total binding with 50μg/ml rhS100A12.  The inset 
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: Ca2＋, Mg2＋
: Ca2＋, Mg2＋, Zn2＋
: Ca2＋, Zn2＋
: Ca2＋
Fig. 4　 The eﬀects of divalent cations on rsRAGE binding to 
rhS100A12.  The plate was coated with 50μg/ml rhS100A12,  and 
25μg/ml rsRAGE was added to each well.  Ca2＋,  Zn2＋,  and Mg2＋ 
were added to the wells indicated at the start of plate coating and 
were present throughout the period immediately before the ﬁnal 
reaction.  The results were the means ± SEM of 3 independent 
experiments.  ＊P＜0.05,  ＊＊P＜0.01 compared with the value with 
no divalent cations.
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reported to be a receptor for several ligands including 
HMGB1,  S100A12,  S100A8/9,  AGEs,  and Aβ.  
RAGE belongs to the immunoglobulin superfamily and 
has 3 immunoglobulin-like domain structures in the 
extracellular portion.  We used recombinant human 
soluble RAGE with a 6-histidine tag at the C-terminus 
for the in vitro binding and established the binding 
assay of HMGB1 or S100A12 to RAGE.
　 The binding of rhHMGB1 to rsRAGE was concen-
tration-dependent and time-dependent (Fig.  1 and Fig.  
2).  The binding was saturable in terms of both rhH-
MGB1 and rsRAGE concentration for constant levels 
of the pair.  rhS100A12 binding to rsRAGE was 
dependent on divalent cations (Fig.  4 and Fig.  5),  
208 Acta Med.  Okayama　Vol.  63,  No.  4Liu et al.
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Fig. 6　 Puriﬁcation of rsRAGE using heparin-sepharose aﬃnity chromatography.  Partially puriﬁed rsRAGE preparations by using a 
Ni-NTA column (lane 1) were applied to heparin-sepharose.  The bound proteins were eluted with 600mM NaCl (lanes 4-11) after extensive 
washing (lanes 2 and 3).  The eluted samples were electrophoresed on 12% separation gel,  and SDS-PAGE gel was stained with 
Coomassie brilliant blue.










1 mM Ca2＋Ca2＋ (－)
Fig. 7　 rhS100A12 binding to heparin-sepharose.  rhS100A12 was mixed with heparin-sepharose for 3h at 4°C under diﬀerent Ca2＋ 
condition.  After incubation,  the supernatant (S) and the sepharose gel (G) were electrophoresed on 15% separation gel,  and the SDS-
PAGE gel was stained with Coomassie brilliant blue.  Lane 1,  loading S100A12.
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whereas HMGB1 was not (Fig.  3).  It is well known 
that S100A12 belongs to the EF-hand Ca2＋ binding 
protein and forms a typical structure.  X-ray crystal-
lography analysis revealed both Ca2＋ and Zn2＋ binding 
sites on the structure of S100A12 [25].  The depen-
dence of S100A12 binding to RAGE in the presence 
of Ca2＋ and Zn2＋ strongly suggested that the restrict 
structure of S100A12 mentioned above was required 
for its binding to RAGE.  In contrast,  rhHMGB1 
binding to rsRAGE was not inﬂuenced by the presence 
of divalent cations.  Thus,  the eﬀects of Ca2＋ and 
Zn2＋ were speciﬁc for S100A12.  The binding site of 
HMGB1 or S100A12 on RAGE has been postulated 
from crystallographic studies.  Hofmann et al. [26] 
suggested that S100A12 may bind to the V-domain of 
RAGE.  On the other hand,  there is controversy as to 
the binding site of HMGB1 on RAGE.  Apparently,  
the aﬃnity of HMGB1 (Kd＝0.71µM) to RAGE was 
higher than that of S100A12 (Kd＝1.39µM).
　 Since rsRAGE was able to be puriﬁed by heparin-
sepharose aﬃnity chromatography (Fig.  6),  it was 
considered to bind to heparin,  and rhS100A12 was 
also found to bind to heparin in the presence of Ca2＋ 
(Fig.  7).  By using the binding assay,  we reported for 
the ﬁrst time that heparin had inhibitory eﬀects on the 
binding of rsRAGE to rhHMGB1 or rhS100A12.  
Dose-dependent inhibitory eﬀects of UFH and LMWH 
on the binding of rsRAGE to rhHMGB1 (Fig.  8) or 
rhS100A12 (Fig.  9) were demonstrated.  UFH is a 
heterogeneous mixture of polysaccharides and has been 
clinically used as an anticoagulant.  LMWH 5000 Da 
is obtained through chemical or enzymatic depolymer-
ization of UFH and shows advantages in overcoming 
some of the limitations associated with the use of 
UFH.  For instance,  compared with UFH,  LMWH 
5000 Da more potently inhibits factor Xa,  an essential 
component of the prothrombinase complex leading to 
the formation of thrombin [27-30].  The exact mecha-
nisms by which heparin blocks the binding of rhH-
MGB1 or rhS100A12 to rsRAGE remain unclear 
under this situation.  Considering that HMGB1 and 
RAGE are all heparin-binding proteins [21,  22-24],  
we hypothesize that one blocking mechanism could be 
heparin occupancy of the binding site on rsRAGE 
and/or rhHMGB1.  However,  further experiments are 
necessary for the analysis of molecular interaction 
between rsRAGE and its ligands.
　 It has been suggested that heparin functions as an 
anti-inﬂammation agent by aﬀecting some components 
in the inﬂammatory cascade,  such as complement 
activation,  platelet activating factor production [31],  
and expression of P- and L- selectins [32].  In addi-
tion,  heparin binds antithrombin III to form a complex 
capable of inhibiting thrombin proteolytic activity.  
This inhibition prevents clot formation and allows 
heparin to be utilized clinically as an anticoagulant 
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Fig. 8　 Eﬀects of heparin with diﬀerent molecular sizes on 
rsRAGE binding to rhHMGB1.  The diﬀerent concentrations of UFH 
(■),  LMWH 5000 Da (▲),  and LMWH 3000 Da (●) were incu-
bated with 25μg/ml rsRAGE for 30min at 4°C,  and the mixture was 
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Fig. 9　 Eﬀects of heparin with diﬀerent molecular sizes on 
rsRAGE binding to rhS100A12.  The diﬀerent concentration of UFH 
(■),  LMWH 5000 Da (▲),  and LMWH 3000 Da (●) were incu-
bated with 25μg/ml rsRAGE for 30min at 4°C,  and the mixture was 
added to the wells.  The results were the mean ± SEM of 3 inde-
pendent experiments.
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[33].  The concept that coagulation can play a role in 
the inﬂammatory response has been well illustrated 
[34].  In acute inﬂammatory diseases,  like sepsis,  
inﬂammatory and coagulation systems coexist in deli-
cate homeostasis [35],  augment each other,  and 
combine to inﬂuence disease progression [36,  37].  
Accordingly,  heparinʼs anti-inﬂammatory eﬀect may be 
partly assigned to its own anticoagulant property.  The 
present results imply that another anti-inﬂammatory 
mechanism of heparin might be the interference eﬀect 
on the interaction between RAGE and its ligands.
　 RAGE has been considered a central player in the 
inﬂammatory response [38].  It is expressed at low 
levels in normal tissues and in the vasculature,  but 
becomes upregulated at sites where its ligands accu-
mulate [39].  The RAGE axis is involved in the 
pathogenesis of a wide range of inﬂammatory disor-
ders via the integration of ligands.  HMGB1 activated 
Mac-1 as well as Mac-1-mediated adhesive and migra-
tory functions of neutrophils in a RAGE-dependent 
manner [40].  Interaction of S100A12 with cellular 
RAGE on vascular endothelial cells,  mononuclear 
phagocytes,  and lymphocytes triggers cellular activa-
tion,  with the expression of VCAM-1,  intercellular 
adhesion molecule-1 (ICAM-1),  and tissue factor (TF) 
as well as production of pro-inﬂammatory mediators 
[15].  Therefore,  the interaction between RAGE and 
its ligands should be a target for inﬂammation-based 
disease intervention.  The in vitro RAGE binding 
established in the present study will provide a conve-
nient assay system for screening candidate drugs to 
interfere with the binding between RAGE and 
HMGB1/S100A12.
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